Supplements and Featured Publications
Addressing Treatment Adherence With Liquid Drug Formulations in CML and ALL
Volume: 1
Issue: 1
Dissecting Emerging Data in Metastatic Breast Cancer
Volume: 1
Issue: 1
The Evolving Role of ESR1 Mutations in Metastatic Breast Cancer
Volume: 1
Issue: 1
This supplement is funded by AstraZeneca. The publisher is solely responsible for this content. AstraZeneca does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this supplement is not medical advice and does not replace independent medical judgment.
Targeting c-MET in Advanced Non–Small Cell Lung Cancer
Volume: 1
Issue: 1
Diving Into Therapeutic Decision-Making in Later-Line CLL
Volume: 1
Issue: 1
Molecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast Cancer
Volume: 1
Issue: 1
The Evolution of Molecular Testing and Targeted Therapy in HR+/HER2– Breast Cancer
Volume: 1
Issue: 1
Treatment Considerations and Evolving Data in Advanced Melanoma After Checkpoint Inhibition
Volume: 1
Issue: 1
A dive into treatment considerations and ongoing research for advanced melanoma after PD-1 inhibition.
Furthering Treatment With Novel Therapies and Multidisciplinary Care in Advanced Melanoma After PD-1 Inhibition
Volume: 01
Issue: 01
Therapeutic Advances and AE Management in NF1-Associated Plexiform Neurofibromas
Volume: 1
Issue: 1
Defining Frontline Treatment Considerations in Advanced Urothelial Carcinoma
Volume: 1
Issue: 1
Moving the Needle With Checkpoint Inhibition in MCC and SCAC
Volume: 1
Issue: 1
2025 Genitourinary Cancers Symposium Priority Report
Volume: 1
Issue: 1
Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
Volume: 1
Issue: 1
Treatment Trends in Adult and Pediatric Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Treatment Trends and Ongoing Research in Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Moving the Needle With JAK Inhibition in Myelofibrosis
Volume: 1
Issue: 1
Menin Inhibition Makes Waves for KMT2A-Rearranged AML
Volume: 1
Issue: 1
Managing Ocular and Other Adverse Effects Associated With Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Volume: 1
Issue: 1
Dissecting Ongoing Research With Oncolytic Viruses in Melanoma
Volume: 1
Issue: 1
ASH 2024: Priority Report: Updates in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Experts detail updates in myeloproliferative neoplasms from the 2024 ASH Annual Meeting & Exposition.
Updates for BTK Inhibitors in CLL Around ASH 2024
Volume: 1
Issue: 1
Experts detail updates regarding BTK inhibitors in chronic lymphocytic leukemia around the 2024 ASH Annual Meeting.
Pancreatic Cancer Awareness Month: Updates in Ongoing Research in RAS Inhibition
Volume: 1
Issue: 1
Making the Most of MRD Assessment, Checkpoint Inhibition in Colorectal Cancer
Volume: 1
Issue: 1
Prostate Cancer Awareness Month: Updates in mCRPC and Radioligand Therapy
Volume: 1
Issue: 1
Exacting the Role of Novel Endocrine Therapies in ER+ Metastatic Breast Cancer
Volume: 1
Issue: 1
Taking Stock of Long-Term Data With TKIs in CML
Volume: 1
Issue: 1
Integrating the Glucocorticoid Receptor Pathway Into Ovarian Cancer Management
Volume: 1
Issue: 1
Harnessing the Activity of Targeted Therapy in HER2-Mutant NSCLC
Volume: 1
Issue: 1
ESMO 2024: Priority Report: Updates in Renal Cell Carcinoma
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5